Skip to content

Comparison of Efficacy and Mechanisms of Different Transplantation Routes of Washed Microbiota Transplantation in Treating Malnutrition Complicated by Gastroduodenal Reconstruction Surgery

Comparison of Efficacy and Mechanisms of Different Transplantation Routes of Washed Microbiota Transplantation in Treating Malnutrition Complicated by Gastroduodenal Reconstruction Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115535
Enrollment
Unknown
Registered
2025-12-28
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malnutrition after gastrointestinal reconstruction surgery

Interventions

Midgut-tube Washed Microbiota Transplantation Group:Midgut-tube Washed Microbiota Transplantation
Colon-TET Washed Microbiota Transplantation Group:Colon-TET Washed Microbiota Transplantation

Sponsors

The Second Affiliated Hospital of Hainan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 70 years, inclusive, regardless of sex 2.Having undergone gastroduodenal reconstruction surgery (Billroth II or Roux-en-Y procedure) at least six months prior 3.Experiencing a weight loss of >5% compared to the post-operative baseline weight (6 months after surgery) over the past six months without intentional dieting, or for patients with a baseline BMI 2% over the past six months 4.An NRS2002 score of >=3 points 5.Failure to respond to conventional nutritional support therapy for >=2 months 6.Ability to provide informed consent.

Exclusion criteria

Exclusion criteria: 1.Expected survival of less than 3 months 2.Edema or ascites resulting from malnutrition 3.Albumin level 2 mg/dL or 177 µmol/L) or abnormal liver function (ALT > 2× upper limit of normal) 13.moderate to severe chronic obstructive pulmonary disease 14.severe hypertension or history of cerebrovascular accident 15.congestive heart failure or unstable angina 16.Patients with food allergies

Design outcomes

Primary

MeasureTime frame
Clinical Response Rate; Clinical Remission Rate;Total Lymphocyte Count;High-Sensitivity C-Reactive Protein;

Secondary

MeasureTime frame
Serum Albumin;Total Protein;Prealbumin;Hemoglobin;Cholesterol;Transferrin;

Countries

China

Contacts

Public ContactFeihu Bai

The Second Affiliated Hospital of Hainan Medical University

baifeihu_hy@163.com+86 898 6680 2026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026